These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

223 related items for PubMed ID: 21821855

  • 1. Predictors of mortality in patients with chronic kidney disease and an implantable defibrillator: an EPGEN substudy.
    Williams ES, Shah SH, Piccini JP, Sun AY, Koontz JI, Al-Khatib SM, Hranitzky PM.
    Europace; 2011 Dec; 13(12):1717-22. PubMed ID: 21821855
    [Abstract] [Full Text] [Related]

  • 2. Survival in octogenarians receiving implantable defibrillators.
    Koplan BA, Epstein LM, Albert CM, Stevenson WG.
    Am Heart J; 2006 Oct; 152(4):714-9. PubMed ID: 16996846
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Long-term follow-up of implantable cardioverter-defibrillator for secondary prevention in chagas' heart disease.
    Martinelli M, de Siqueira SF, Sternick EB, Rassi A, Costa R, Ramires JA, Kalil Filho R.
    Am J Cardiol; 2012 Oct 01; 110(7):1040-5. PubMed ID: 22727179
    [Abstract] [Full Text] [Related]

  • 5. Implantable cardioverter-defibrillators in patients with CKD: a propensity-matched mortality analysis.
    Nakhoul GN, Schold JD, Arrigain S, Harb SC, Jolly S, Wilkoff BL, Nally JV, Navaneethan SD.
    Clin J Am Soc Nephrol; 2015 Jul 07; 10(7):1119-27. PubMed ID: 26111859
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Relations among renal function, risk of sudden cardiac death, and benefit of the implanted cardiac defibrillator in patients with ischemic left ventricular dysfunction.
    Goldenberg I, Moss AJ, McNitt S, Zareba W, Andrews ML, Hall WJ, Greenberg H, Case RB, Multicenter Automatic Defibrillator Implantation Trial-II Investigators.
    Am J Cardiol; 2006 Aug 15; 98(4):485-90. PubMed ID: 16893702
    [Abstract] [Full Text] [Related]

  • 8. Effect of concomitant antiarrhythmic therapy on survival in patients with implantable cardioverter defibrillators.
    Ho AT, Pai SM, Timothy P, Pai RG.
    Pacing Clin Electrophysiol; 2005 Jul 15; 28(7):647-53. PubMed ID: 16008799
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Implantable cardioverter-defibrillator efficacy in patients with heart failure and left ventricular dysfunction (from the MADIT II population).
    Zareba W, Piotrowicz K, McNitt S, Moss AJ, MADIT II Investigators.
    Am J Cardiol; 2005 Jun 15; 95(12):1487-91. PubMed ID: 15950580
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Impact of left ventricular ejection fraction on occurrence of ventricular events in defibrillator patients with coronary artery disease.
    Schaer B, Sticherling C, Szili-Torok T, Osswald S, Jordaens L, Theuns DA.
    Europace; 2011 Nov 15; 13(11):1562-7. PubMed ID: 21712284
    [Abstract] [Full Text] [Related]

  • 13. Predictive value of fragmented QRS in primary prevention implantable cardioverter defibrillator recipients with left ventricular dysfunction.
    Forleo GB, Della Rocca DG, Papavasileiou LP, Panattoni G, Sergi D, Duro L, Mahfouz K, Magliano G, Santini L, Romeo F.
    J Cardiovasc Med (Hagerstown); 2011 Nov 15; 12(11):779-84. PubMed ID: 21941203
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Renal dysfunction in patients with heart failure with preserved versus reduced ejection fraction: impact of the new Chronic Kidney Disease-Epidemiology Collaboration Group formula.
    McAlister FA, Ezekowitz J, Tarantini L, Squire I, Komajda M, Bayes-Genis A, Gotsman I, Whalley G, Earle N, Poppe KK, Doughty RN, Meta-analysis Global Group in Chronic Heart Failure (MAGGIC) Investigators.
    Circ Heart Fail; 2012 May 01; 5(3):309-14. PubMed ID: 22441773
    [Abstract] [Full Text] [Related]

  • 16. Prevalence and prognostic impact of comorbidities in heart failure patients with implantable cardioverter defibrillator.
    Bruch C, Bruch C, Sindermann J, Breithardt G, Gradaus R.
    Europace; 2007 Aug 01; 9(8):681-6. PubMed ID: 17507354
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Effectiveness of implantable defibrillators in octogenarians and nonagenarians for primary prevention of sudden cardiac death.
    Mezu U, Adelstein E, Jain S, Saba S.
    Am J Cardiol; 2011 Sep 01; 108(5):718-22. PubMed ID: 21640321
    [Abstract] [Full Text] [Related]

  • 19. Ventricular arrhythmias among implantable cardioverter-defibrillator recipients for primary prevention: impact of chronic total coronary occlusion (VACTO Primary Study).
    Nombela-Franco L, Mitroi CD, Fernández-Lozano I, García-Touchard A, Toquero J, Castro-Urda V, Fernández-Diaz JA, Perez-Pereira E, Beltrán-Correas P, Segovia J, Werner GS, Javier G, Luis AP.
    Circ Arrhythm Electrophysiol; 2012 Feb 01; 5(1):147-54. PubMed ID: 22205684
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.